Clinical Trial Update: A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the safety and potential activity of intramuscular BB-301 in individuals with oculopharyngeal muscular dystrophy with d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oculopharyngeal Muscular Dystrophy

Drugs mentioned

• BB-301

Snippet

Sponsor: Benitec Biopharma, Inc. | Conditions: Oculopharyngeal Muscular Dystrophy | Phase 1, Phase 2 | Status: RECRUITING